CT-155 is a smartphone app that integrates psychosocial interventions delivered using an adaptive goal-setting technique. A ...
Panelists discuss how the CONVOKE clinical trial was designed as a 16-week study focusing specifically on patients with ...
Schizophrenia is a chronic psychiatric disorder that requires lifelong management, with consistent medication adherence essential to prevent relapse and disability. Counseling that emphasizes empathy, ...
Credit: Getty Images A literature review of nonpharmacologic treatments for patients with schizophrenia and comparison recommendations in the 2020 American Psychiatric Association Practice (APA) ...
ENIGMA-TRS 1 is an international, one-year, double-blind, placebo-controlled Phase III study in at least 600 patients; enrollment to start imminently; 12-week study results expected in Q4 2026 ...
Boehringer Ingelheim and Click Therapeutics today shared data from the pivotal Phase III CONVOKE study (NCT05838625) of CT-155 (BI 3972080), an investigational prescription digital therapeutic ...
German drugmaker Boehringer Ingelheim and Click Therapeutics said their phase 3 trial of a prescription digital therapeutic ...
A new study from Case Western Reserve University suggests a major shift in schizophrenia treatment: One that focuses on ...
ALTO-101 is an investigational phosphodiesterase-4 (PDE4) inhibitor delivered via a transdermal patch. Inhibition of the PDE4 enzyme is expected to enhance neural circuits and improve cognitive ...
Detailed price information for Alto Neuroscience Inc (ANRO-N) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback